Astellas now has a pair of studies backing the use of its Claudin 18.2 targeting antibody zolbetuximab in gastric cancer, setting up regulatory filings and consolidating i
Tech companies Mitsui and NVIDIA have joined forces to develop what they say is the world’s first generative artificial intelligence supercomputer designed for use in phar
Shares in Astellas Pharma were weaker this morning on the news that the FDA has delayed its review of one of its top pipeline prospects – menopause drug fezolinetant – by
Kenji Yasukawa is stepping down as chief executive of Japanese pharma group Astellas, to be succeeded by Naoki Okamura – currently chief strategy officer – on 1st April.
With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with the acquisition of global rights to mainstay antifungal drug Mycamine from
Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t